‘It Came out of Nowhere’: The Rise of Dr Pepper

06/07/24 • 21 min

10 Listeners

There is a new contender in the cola wars, and it isn’t a cola. It’s Dr Pepper. WSJ’s Jennifer Maloney unpacks how after decades as a distant competitor, Dr Pepper has climbed the soda ranks with help from hefty marketing, novel flavors and TikTok videos.

Further Reading:

Dr Pepper Ties Pepsi as America’s No. 2 Soda

Further Listening:

The Agony and Ecstasy of Tab

Learn more about your ad choices. Visit megaphone.fm/adchoices

Further Reading:

Dr Pepper Ties Pepsi as America’s No. 2 Soda

Further Listening:

The Agony and Ecstasy of Tab

Learn more about your ad choices. Visit megaphone.fm/adchoices

Previous Episode

Why Biden Is Cracking Down on Asylum at the Border

President Biden unveiled a last-ditch effort to lower illegal crossings at the southern border this week. The move focuses on asylum seekers, and the policy is similar to one that former President Trump tried in 2018. WSJ’s Michelle Hackman describes the policy and tries to answer the question: why now?

Further Reading:

-Biden Issues Executive Actions on Immigration: What to Know

Further Listening:

-What the End of Title 42 Means for U.S. Immigration Policy

-What Trump's Immigration Restrictions Could Mean for the Economy

Learn more about your ad choices. Visit megaphone.fm/adchoices

Next Episode

Trillion Dollar Shot, Episode 4: The Disruptors

The rising popularity of GLP-1 drugs could cause all kinds of ripple effects.

According to one estimate, 9% of the U.S. population could be on Ozempic or similar medications by 2030. Meanwhile, drugmakers are already developing the next generation of weight-loss drugs and researchers are studying the possible health benefits beyond weight loss and diabetes, including addiction.

In the final episode of our series we ask: What could all this development mean for businesses, from the food sector to airlines? And who wins and who loses in the post-Ozempic economy?

Guests include: David Ricks, CEO of Eli Lilly; and Mehdi Farokhnia, an addiction researcher at the National Institutes of Health.

Listen to Episodes 1, 2 and 3 of “Trillion Dollar Shot” here.

Learn more about your ad choices. Visit megaphone.fm/adchoices